Objectives: This study aimed to determine the patient characteristics, treatment procedures, and medical costs of methicillin-resistant infections in clinical practice in Japan.
Methods: Using the MinaCare database of healthcare information covering nearly 3 million individuals, of which 90% were aged 20-59 years, we extracted and analyzed data of patients who were aged ⩾15 years and diagnosed with methicillin-resistant during hospitalization between April 2010 and August 2015.
Results: A total of 684 patients with methicillin-resistant infection were listed in the database, of which 365 were eligible to be included in this study. Mean patient age was 52.9 years, and 31.5% of the patients were females. Methicillin-resistant bacteremia was the most common methicillin-resistant infection (32.9%) with a mean age of 48.5 years, followed by pneumonia (24.1%) with a mean age of 61.0 years and methicillin-resistant surgical site infection (6.3%) with a mean age of 49.7 years. Vancomycin was the most frequently prescribed anti-methicillin-resistant drug used as the first-line therapy (68.5%), followed by teicoplanin (14.2%), linezolid (7.9%), arbekacin (5.8%), and daptomycin (3.6%). The mortality rate was 11.0%, and the mean treatment duration was 13.3 days. The median total medical cost per patient was US$5083. The median treatment cost for methicillin-resistant bacteremia was the highest among the methicillin-resistant infections at US$9099, followed by methicillin-resistant pneumonia at US$3676 and surgery site infections at US$2084.
Conclusion: Although the proportion of patients with methicillin-resistant is very small in the employment-based health insurance database, methicillin-resistant bacteremia is the most common methicillin-resistant infection in the working-age population and requires the highest medical cost. Methicillin-resistant pneumonia is more common in the elderly and is a cause of high mortality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710669 | PMC |
| http://dx.doi.org/10.1177/2050312119871181 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antibiotic Resistance of Strains-Searching for New Antimicrobial Agents-Review.
Pharmaceuticals (Basel)
January 2025
MML Medical Centre, Bagno 2, 00-112 Warsaw, Poland.
Inappropriate and excessive use of antibiotics is responsible for the rapid development of antimicrobial resistance, which is associated with increased patient morbidity and mortality. There is an urgent need to explore new antibiotics or alternative antimicrobial agents. a commensal microorganism but is also responsible for numerous infections.
View Article and Find Full Text PDFThe Changes in the Antibiotic Resistance of , , and in the Clinical Isolates of a Multiprofile Hospital over 6 Years (2017-2022).
J Clin Med
January 2025
Department of Medical Biology, Faculty of Nursing and Midwifery, Wroclaw Medical University, 50-368 Wroclaw, Poland.
The growing resistance of bacteria to antibiotics is a serious problem in health care. The present study aims to assess the drug resistance of , , and isolated from infections in a multispecialty hospital over a 6-year period. Identification and antimicrobial susceptibility testing were performed using the VITEK2 automated system (Biomerieux).
View Article and Find Full Text PDFDiscovery of Quinazolone Pyridiniums as Potential Broad-Spectrum Antibacterial Agents.
Molecules
January 2025
Institute of Bioorganic & Medicinal Chemistry, Key Laboratory of Applied Chemistry of Chongqing Municipality, School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, China.
The overprescription of antibiotics in medicine and agriculture has accelerated the development and spread of antibiotic resistance in bacteria, which severely limits the arsenal available to clinicians for treating bacterial infections. This work discovered a new class of heteroarylcyanovinyl quinazolones and quinazolone pyridiniums to surmount the increasingly severe bacterial resistance. Bioactive assays manifested that the highly active compound exhibited strong inhibition against MRSA and with extremely low MICs of 0.
View Article and Find Full Text PDFData Mining Models in Prediction of Vancomycin-Intermediate in Methicillin-Resistant (MRSA) Bacteremia Patients in a Clinical Care Setting.
Microorganisms
January 2025
Graduate Institute of Human Resource and Knowledge Management, National Kaohsiung Normal University, Kaohsiung 802561, Taiwan.
Vancomycin-intermediate (VISA) is a multi-drug-resistant pathogen of significant clinical concern. Various strains can cause infections, from skin and soft tissue infections to life-threatening conditions such as bacteremia and pneumonia. VISA infections, particularly bacteremia, are associated with high mortality rates, with 34% of patients succumbing within 30 days.
View Article and Find Full Text PDFImplementation of 2% Chlorhexidine Bathing to Reduce Healthcare-Associated Infections Among Patients in the Intensive Care Unit.
Microorganisms
January 2025
Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Healthcare-associated infections (HAIs) significantly increase morbidity, mortality, length of hospital stays, and costs, particularly among ICU patients. Despite standard interventions, catheter-associated urinary tract infections (CAUTI) and central line-associated bloodstream infections (CLABSI) remain major HAI contributors. This study evaluated the efficacy of daily 2% chlorhexidine gluconate (CHG) bathing in reducing HAI incidence, specifically CAUTI, CLABSI, and multidrug-resistant organisms (MDROs), in a 20-bed ICU at a regional hospital.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!